Promptly after the final proration factor is announced, the exchange agent will credit shares of Zoetis common stock for distribution in the exchange offer in book-entry form to accounts maintained by the Zoetis transfer agent for tendering shareholders who have validly tendered and not validly withdrawn their shares of Pfizer common stock. Checks in lieu of fractional shares of Zoetis common stock will be delivered after the exchange agent has aggregated all fractional shares and sold them in the open market.
Following the expiration of the exchange offer, Pfizer converted all of its Zoetis Class B common stock into Zoetis Class A common stock and, as noted above, all such converted Class A common stock will be distributed to Pfizer shareholders who validly tendered and did not validly withdraw their shares of Pfizer common stock. As a result, Pfizer no longer holds any ownership interest in Zoetis. Pfizer continues to expect the full separation of Zoetis to be accretive on a full-year basis to Pfizer’s Adjusted Diluted EPS (2) and Reported Diluted EPS (3) in 2014.
J.P. Morgan Securities LLC, BofA Merrill Lynch, Goldman Sachs & Co. and Morgan Stanley served as the dealer managers for the exchange offer.
2013 Financial Guidance (1)As a result of the full separation of Zoetis, Pfizer will now present Zoetis’ financial results from January 1, 2013 to June 24, 2013 as a discontinued operation. Pfizer is adjusting its 2013 financial guidance solely to reflect the impact of the Zoetis exchange offer. The adjustment reflects modifications to the following components:
- Reported Revenues, Adjusted Cost of Sales as a Percent of Revenues (2), Adjusted SI&A Expenses (2), Adjusted R&D Expenses (2) and Adjusted Other (Income)/Deductions (2) : Actual and projected revenue and expense contributions of Zoetis have been excluded for the full-year 2013 from these components. While such contributions of Zoetis also have been excluded for the full-year 2013 from the Effective Tax Rate on Adjusted Income (2) , this did not result in a change in that component.
Adjusted Diluted EPS
(2): Actual and projected financial
results of Zoetis have been excluded for the full-year 2013 through:
- The presentation of Zoetis financial results as a discontinued operation from January 1, 2013 to June 24, 2013. Zoetis was wholly owned by Pfizer through February 6, 2013, and 80.2% owned by Pfizer from February 7, 2013 to June 24, 2013.
- The removal of the 80.2% of Zoetis projected financial results from June 24, 2013 through December 31, 2013.
Reported Diluted EPS
- As previously mentioned, the financial results of Zoetis from January 1, 2013 to June 24, 2013 are presented as a discontinued operation and, accordingly, continue to impact full-year 2013 guidance for Reported Diluted EPS (3).
- Full-year 2013 guidance for Reported Diluted EPS (3) excludes the 80.2% of Zoetis projected financial results from June 24, 2013 through December 31, 2013.
- Full-year 2013 guidance for Reported Diluted EPS (3) reflects the partial-year benefit of the net reduction (4) in weighted average shares outstanding used to calculate Reported Diluted EPS (3).
- Full-year 2013 guidance for Reported Diluted EPS (3) was not adjusted to reflect the gain on the disposition of shares of Zoetis common stock.
- The impact of the removal of the financial contribution of Zoetis from June 24, 2013 through December 31, 2013, as well as the impact of the partial-year benefit of the net reduction (4) in shares of Pfizer’s outstanding common stock due to the exchange offer, did not result in a change to Pfizer’s projected range for 2013 Reported Diluted EPS (3).
|Reported Revenues||$50.8 to $52.8 billion ( previously $55.3 to $57.3 billion)|
|Adjusted Cost of Sales (2) as a Percent of Revenues||18.0% to 19.0% ( previously 19.0% to 20.0%)|
|Adjusted SI&A Expenses (2)||$14.2 to $15.2 billion ( previously $15.6 to $16.6 billion)|
|Adjusted R&D Expenses (2)||$6.1 to $6.6 billion ( previously $6.5 to $7.0 billion)|
|Adjusted Other (Income)/Deductions (2)||Approximately $800 million ( previously approximately $900 million)|
|Effective Tax Rate on Adjusted Income (2)||Approximately 28.0%|
|Reported Diluted EPS (3)||$1.44 to $1.59|
|Adjusted Diluted EPS (2)||$2.10 to $2.20 (previously $2.14 to $2.24)|
- Does not assume the completion of any business development transactions not completed as of March 31, 2013, including any one-time upfront payments associated with such transactions, except for the Zoetis exchange offer.
- Reflects the impact of the Zoetis exchange offer, except for the gain on the disposition of shares of Zoetis common stock.
- Excludes the potential effects of the resolution of litigation-related matters not substantially resolved as of March 31, 2013.
- Assumes exchange rates that are a blend of the actual exchange rates in effect during the first three months of 2013 and the mid-April 2013 exchange rates for the remainder of the year.
|($ in billions, except per share amounts)|
|Income/(Expense)||Net Income||Diluted EPS|
|Adjusted Income/Diluted EPS (2) Guidance||~$14.4-$15.1||~$2.10-$2.20|
|Purchase accounting impacts of transactions completed as of March 31, 2013||(3.4)||(0.50)|
|Acquisition-related costs||(0.4 - 0.5)||(0.06 - 0.07)|
|Certain other items, including non-acquisition-related restructuring costs||(0.5 – 0.8)||(0.08 - 0.12)|
|Reported Net Income Attributable to Pfizer Inc./Diluted EPS (3) Guidance||~$9.9-$11.0||~$1.44-$1.59|
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV